MK-0822

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2011
0120082011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Odanacatib (ODN, MK-0822) is an investigational drug under development for the treatment of osteoporosis. A quantitative LC/MS-MS… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
Review
2011
Review
2011
Bone homeostasis is maintained by delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts… (More)
Is this relevant?
Review
2009
Review
2009
Odanacatib (MK-0822, MK-822) is an orally administered cathepsin K inhibitor being developed by Merck & Co Inc, under license… (More)
Is this relevant?
2009
2009
An enantioselective synthesis of the Cathepsin K inhibitor odanacatib (MK-0822) 1 is described. The key step involves the novel… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of… (More)
Is this relevant?